Ariad Pharm Inc (ARIA) 9.71 $ARIA
After Yesterday's Rally of 1.05% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Aug 01, 4:30PM CDT
Ariad Pharmaceuticals (NASDAQ:ARIA) traded in a range yesterday that spanned from a low of $9.44 to a high of $9.90. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $9.89 on volume of 3.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ARIA: 9.71 (+0.20)
PDL BioPharma Completes Second Tranche Payment Under Royalty Transaction with ARIAD Pharmaceuticals
PR Newswire - Mon Aug 01, 3:02PM CDT
PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that it has funded the second tranche of $50 million to ARIAD Pharmaceuticals, Inc. (ARIAD) (NASDAQ: ARIA) which was due on the first anniversary of the closing date under the terms of the ARIAD Royalty Agreement. This agreement was entered into in July 2015, in exchange for royalties on the net revenues of Iclusig® (ponatinib). As a result of the second tranche payment, under the terms of the ARIAD Royalty Agreement, PDL's royalty percentage will increase to 5.0% of the U.S. and European net revenues of Iclusig and 5.0% of the payments ARIAD receives elsewhere in the world until December 31, 2018 (subject to agreed-upon annual maximum payments). Beginning January 1, 2019 and thereafter, the royalty rate will increase to 6.5% in all jurisdictions and continue until December 31, 2033, subject to a put option of PDL upon the occurrence of specified events and a call option of ARIAD.
ARIA: 9.71 (+0.20), PDLI: 3.55 (+0.03)
Bank of America trade offers a 9% return in 204 days, or find similar option trades on Ariad Pharmaceuticals, US Steel, CyberArk Software, and Abbott Laboratories
PR Newswire - Fri Jul 29, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for ABT, ARIA, BAC, CYBR, and X.
ABT: 45.29 (+0.54), CYBR: 56.48 (+0.09), BAC: 14.33 (-0.16), ARIA: 9.71 (+0.20), X: 26.57 (-0.92)
ARIAD's (ARIA) Stock Up on Q2 Earnings & Revenue Beat
Arpita Dutt - Zacks Investment Research - Fri Jul 29, 8:23AM CDT
ARIAD (ARIA) swung to earnings in the second quarter while Iclusig sales continued to grow.
ZTS: 50.40 (-0.07), INCY: 90.00 (-0.21), ARIA: 9.71 (+0.20), NKTR: 17.76 (+0.47)
Ariad Pharmaceuticals Set to Possibly Pullback After Yesterday's Rally of 10.45%
Comtex SmarTrend(R) - Thu Jul 28, 1:22PM CDT
Ariad Pharmaceuticals (NASDAQ:ARIA) traded in a range yesterday that spanned from a low of $8.80 to a high of $9.38. Yesterday, the shares gained 10.5%, which took the trading range above the 3-day high of $8.45 on volume of 9.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ARIA: 9.71 (+0.20)
ARIAD (ARIA) Swings to Earnings in Q2, Revenues Beat
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 8:12AM CDT
ARIAD (ARIA) posted better-than-expected results in Q2 with revenues benefiting from a one-time impact related to revenue recognition in France.
ARIA: 9.71 (+0.20)
ARIAD Reports Second Quarter and First Half 2016 Financial Results
BusinessWire - Thu Jul 28, 6:34AM CDT
--~U.S. product revenue of $32.6 million for Q2 2016, representing 50% growth from prior year
ARIA: 9.71 (+0.20)
Watch for Drug Stocks Earnings on Jul 28: BMY, CELG & More
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 8:47AM CDT
How will drug stocks Bristol-Myers, Celgene and others perform when they report Q2 results on Jul 28, before the opening bell?
AGEN: 5.65 (+0.10), BIIB: 301.83 (+11.90), ABT: 45.29 (+0.54), JNJ: 125.40 (+0.17), GILD: 80.46 (+0.99), ALXN: 133.50 (+4.90), ARIA: 9.71 (+0.20), BMY: 76.19 (+1.38), CELG: 114.69 (+2.50), NVS: 83.07 (-0.19)
ARIAD (ARIA) to Report Q2 Earnings: Will the Stock Surprise?
Arpita Dutt - Zacks Investment Research - Tue Jul 26, 5:58AM CDT
Focus will remain on the performance of ARIAD's (ARIA) leukemia drug, Iclusig.
BMRN: 100.25 (+0.83), INCY: 90.00 (-0.21), AMGN: 174.16 (+2.13), ARIA: 9.71 (+0.20)
Watch for Ariad Pharmaceuticals to Potentially Rebound After Falling 1.90% Yesterday
Comtex SmarTrend(R) - Wed Jul 13, 2:12PM CDT
Ariad Pharmaceuticals (NASDAQ:ARIA) traded in a range yesterday that spanned from a low of $7.16 to a high of $7.43. Yesterday, the shares fell 1.9%, which took the trading range below the 3-day low of $7.24 on volume of 1.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ARIA: 9.71 (+0.20)
Biotechnology Equities Under the Scanner - Exelixis, Novavax, Celgene, and Ariad Pharma
PR Newswire - Thu Jul 07, 7:00AM CDT
On Wednesday, July 06, 2016, the NASDAQ Composite ended the trading session at 4,859.16, up 0.75%; the Dow Jones Industrial Average edged 0.44% higher, to finish at 17,918.62; and the S&P 500 closed at 2,099.73, up 0.54%. The gains were broad based as eight out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Exelixis Inc. (NASDAQ: EXEL), Novavax Inc. (NASDAQ: NVAX), Celgene Corporation (NASDAQ: CELG), and Ariad Pharmaceuticals Inc. (NASDAQ: ARIA). Learn more about these stocks by accessing their free notes at:
NVAX: 7.35 (+0.03), ARIA: 9.71 (+0.20), CELG: 114.69 (+2.50), EXEL: 9.27 (+0.09), CELGZ: 1.14 (-0.02)
ARIAD Announces Distribution Agreements for Iclusig(R) in Latin America and the Middle East/North Africa
BusinessWire - Fri Jun 17, 6:45AM CDT
--~ Agreements Include Buy-Back Provisions in Case of a Change in Control of ARIAD
ARIA: 9.71 (+0.20)
ARIAD (ARIA) Presents Long-Term Phase II Data on Iclusig
Zacks Equity Research - Zacks Investment Research - Tue Jun 14, 5:25PM CDT
ARIAD (ARIA) presented long-term follow-up phase II PACE study data on its leukemia drug, Iclusig.
ARIA: 9.71 (+0.20), BMY: 76.19 (+1.38), ORPN: 1.62 (-0.10), NVS: 83.07 (-0.19)
ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib from Phase 2 Pace Clinical Trial
BusinessWire - Mon Jun 13, 6:35AM CDT
--~ Overall Survival at Four Years is Estimated to be 77 Percent
ARIA: 9.71 (+0.20)
Shares of ARIA Up 48.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Jun 10, 12:15AM CDT
SmarTrend identified an Uptrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on March 1st, 2016 at $5.66. In approximately 3 months, Ariad Pharmaceuticals has returned 48.76% as of today's recent price of $8.42.
ARIA: 9.71 (+0.20)
ARIAD to Host Analyst & Investor Day in New York City
BusinessWire - Wed Jun 08, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will host an Analyst & Investor Day for its research analysts and institutional investors on Friday, June 17 at 8:30 a.m. (EDT) in New York City. Paris Panayiotopoulos, president and chief executive officer of ARIAD, will host the event along with other key members of ARIAD senior management. The meeting will focus on ARIAD's completion of its corporate strategic review, as well as provide an update on continued progress in its research and development and commercial programs. Expert medical leaders in the fields of chronic myeloid leukemia and non-small cell lung cancer will be featured speakers and discussants at the meeting.
ARIA: 9.71 (+0.20)
ARIAD (ARIA) Presents Phase II Study Data on Cancer Drug
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 11:00AM CDT
ARIAD (ARIA) presented updated phase II ALTA study data on brigatinib for the treatment of refractory ALK+ non-small cell lung cancer patients.
ATNM: 1.71 (-0.07), PFE: 37.31 (+0.42), JNP: 7.50 (-0.04), ARIA: 9.71 (+0.20)
Ariad Pharmaceuticals Set to Possibly Rebound After Yesterday's Selloff of 1.22%
Comtex SmarTrend(R) - Mon Jun 06, 4:17PM CDT
Ariad Pharmaceuticals (NASDAQ:ARIA) traded in a range yesterday that spanned from a low of $8.58 to a high of $9.12. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $8.63 on volume of 5.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ARIA: 9.71 (+0.20)
Covered Call Alerts For Canadian Solar, BP, Lumber Liquidators, Ariad Pharmaceuticals and Walmart Stores Inc. Released By InvestorsObserver
PR Newswire - Mon Jun 06, 9:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for CSIQ, BP, LL, ARIA and WMT.
WMT: 73.78 (+0.81), BP: 33.18 (-1.22), LL: 15.31 (+0.28), ARIA: 9.71 (+0.20), CSIQ: 14.77 (+0.57)
ARIAD's Investigational Medicine Brigatinib Demonstrates 54 Percent Confirmed Objective Response Rate and 12.9-Month Median Progression-Free Survival in ALTA Study
BusinessWire - Mon Jun 06, 6:35AM CDT
--~ Data from Pivotal Study in Refractory ALK Positive Non-Small Cell Lung Cancer Patients
ARIA: 9.71 (+0.20)
After Yesterday's Rally of 1.05% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Aug 01, 4:30PM CDT
Ariad Pharmaceuticals (NASDAQ:ARIA) traded in a range yesterday that spanned from a low of $9.44 to a high of $9.90. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $9.89 on volume of 3.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ARIA: 9.71 (+0.20)
PDL BioPharma Completes Second Tranche Payment Under Royalty Transaction with ARIAD Pharmaceuticals
PR Newswire - Mon Aug 01, 3:02PM CDT
PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that it has funded the second tranche of $50 million to ARIAD Pharmaceuticals, Inc. (ARIAD) (NASDAQ: ARIA) which was due on the first anniversary of the closing date under the terms of the ARIAD Royalty Agreement. This agreement was entered into in July 2015, in exchange for royalties on the net revenues of Iclusig® (ponatinib). As a result of the second tranche payment, under the terms of the ARIAD Royalty Agreement, PDL's royalty percentage will increase to 5.0% of the U.S. and European net revenues of Iclusig and 5.0% of the payments ARIAD receives elsewhere in the world until December 31, 2018 (subject to agreed-upon annual maximum payments). Beginning January 1, 2019 and thereafter, the royalty rate will increase to 6.5% in all jurisdictions and continue until December 31, 2033, subject to a put option of PDL upon the occurrence of specified events and a call option of ARIAD.
ARIA: 9.71 (+0.20), PDLI: 3.55 (+0.03)
Bank of America trade offers a 9% return in 204 days, or find similar option trades on Ariad Pharmaceuticals, US Steel, CyberArk Software, and Abbott Laboratories
PR Newswire - Fri Jul 29, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for ABT, ARIA, BAC, CYBR, and X.
ABT: 45.29 (+0.54), CYBR: 56.48 (+0.09), BAC: 14.33 (-0.16), ARIA: 9.71 (+0.20), X: 26.57 (-0.92)
ARIAD's (ARIA) Stock Up on Q2 Earnings & Revenue Beat
Arpita Dutt - Zacks Investment Research - Fri Jul 29, 8:23AM CDT
ARIAD (ARIA) swung to earnings in the second quarter while Iclusig sales continued to grow.
ZTS: 50.40 (-0.07), INCY: 90.00 (-0.21), ARIA: 9.71 (+0.20), NKTR: 17.76 (+0.47)
Ariad Pharmaceuticals Set to Possibly Pullback After Yesterday's Rally of 10.45%
Comtex SmarTrend(R) - Thu Jul 28, 1:22PM CDT
Ariad Pharmaceuticals (NASDAQ:ARIA) traded in a range yesterday that spanned from a low of $8.80 to a high of $9.38. Yesterday, the shares gained 10.5%, which took the trading range above the 3-day high of $8.45 on volume of 9.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ARIA: 9.71 (+0.20)
ARIAD (ARIA) Swings to Earnings in Q2, Revenues Beat
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 8:12AM CDT
ARIAD (ARIA) posted better-than-expected results in Q2 with revenues benefiting from a one-time impact related to revenue recognition in France.
ARIA: 9.71 (+0.20)
ARIAD Reports Second Quarter and First Half 2016 Financial Results
BusinessWire - Thu Jul 28, 6:34AM CDT
--~U.S. product revenue of $32.6 million for Q2 2016, representing 50% growth from prior year
ARIA: 9.71 (+0.20)
Watch for Drug Stocks Earnings on Jul 28: BMY, CELG & More
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 8:47AM CDT
How will drug stocks Bristol-Myers, Celgene and others perform when they report Q2 results on Jul 28, before the opening bell?
AGEN: 5.65 (+0.10), BIIB: 301.83 (+11.90), ABT: 45.29 (+0.54), JNJ: 125.40 (+0.17), GILD: 80.46 (+0.99), ALXN: 133.50 (+4.90), ARIA: 9.71 (+0.20), BMY: 76.19 (+1.38), CELG: 114.69 (+2.50), NVS: 83.07 (-0.19)
ARIAD (ARIA) to Report Q2 Earnings: Will the Stock Surprise?
Arpita Dutt - Zacks Investment Research - Tue Jul 26, 5:58AM CDT
Focus will remain on the performance of ARIAD's (ARIA) leukemia drug, Iclusig.
BMRN: 100.25 (+0.83), INCY: 90.00 (-0.21), AMGN: 174.16 (+2.13), ARIA: 9.71 (+0.20)
Watch for Ariad Pharmaceuticals to Potentially Rebound After Falling 1.90% Yesterday
Comtex SmarTrend(R) - Wed Jul 13, 2:12PM CDT
Ariad Pharmaceuticals (NASDAQ:ARIA) traded in a range yesterday that spanned from a low of $7.16 to a high of $7.43. Yesterday, the shares fell 1.9%, which took the trading range below the 3-day low of $7.24 on volume of 1.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ARIA: 9.71 (+0.20)
Biotechnology Equities Under the Scanner - Exelixis, Novavax, Celgene, and Ariad Pharma
PR Newswire - Thu Jul 07, 7:00AM CDT
On Wednesday, July 06, 2016, the NASDAQ Composite ended the trading session at 4,859.16, up 0.75%; the Dow Jones Industrial Average edged 0.44% higher, to finish at 17,918.62; and the S&P 500 closed at 2,099.73, up 0.54%. The gains were broad based as eight out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Exelixis Inc. (NASDAQ: EXEL), Novavax Inc. (NASDAQ: NVAX), Celgene Corporation (NASDAQ: CELG), and Ariad Pharmaceuticals Inc. (NASDAQ: ARIA). Learn more about these stocks by accessing their free notes at:
NVAX: 7.35 (+0.03), ARIA: 9.71 (+0.20), CELG: 114.69 (+2.50), EXEL: 9.27 (+0.09), CELGZ: 1.14 (-0.02)
ARIAD Announces Distribution Agreements for Iclusig(R) in Latin America and the Middle East/North Africa
BusinessWire - Fri Jun 17, 6:45AM CDT
--~ Agreements Include Buy-Back Provisions in Case of a Change in Control of ARIAD
ARIA: 9.71 (+0.20)
ARIAD (ARIA) Presents Long-Term Phase II Data on Iclusig
Zacks Equity Research - Zacks Investment Research - Tue Jun 14, 5:25PM CDT
ARIAD (ARIA) presented long-term follow-up phase II PACE study data on its leukemia drug, Iclusig.
ARIA: 9.71 (+0.20), BMY: 76.19 (+1.38), ORPN: 1.62 (-0.10), NVS: 83.07 (-0.19)
ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib from Phase 2 Pace Clinical Trial
BusinessWire - Mon Jun 13, 6:35AM CDT
--~ Overall Survival at Four Years is Estimated to be 77 Percent
ARIA: 9.71 (+0.20)
Shares of ARIA Up 48.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Jun 10, 12:15AM CDT
SmarTrend identified an Uptrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on March 1st, 2016 at $5.66. In approximately 3 months, Ariad Pharmaceuticals has returned 48.76% as of today's recent price of $8.42.
ARIA: 9.71 (+0.20)
ARIAD to Host Analyst & Investor Day in New York City
BusinessWire - Wed Jun 08, 6:35AM CDT
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will host an Analyst & Investor Day for its research analysts and institutional investors on Friday, June 17 at 8:30 a.m. (EDT) in New York City. Paris Panayiotopoulos, president and chief executive officer of ARIAD, will host the event along with other key members of ARIAD senior management. The meeting will focus on ARIAD's completion of its corporate strategic review, as well as provide an update on continued progress in its research and development and commercial programs. Expert medical leaders in the fields of chronic myeloid leukemia and non-small cell lung cancer will be featured speakers and discussants at the meeting.
ARIA: 9.71 (+0.20)
ARIAD (ARIA) Presents Phase II Study Data on Cancer Drug
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 11:00AM CDT
ARIAD (ARIA) presented updated phase II ALTA study data on brigatinib for the treatment of refractory ALK+ non-small cell lung cancer patients.
ATNM: 1.71 (-0.07), PFE: 37.31 (+0.42), JNP: 7.50 (-0.04), ARIA: 9.71 (+0.20)
Ariad Pharmaceuticals Set to Possibly Rebound After Yesterday's Selloff of 1.22%
Comtex SmarTrend(R) - Mon Jun 06, 4:17PM CDT
Ariad Pharmaceuticals (NASDAQ:ARIA) traded in a range yesterday that spanned from a low of $8.58 to a high of $9.12. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $8.63 on volume of 5.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ARIA: 9.71 (+0.20)
Covered Call Alerts For Canadian Solar, BP, Lumber Liquidators, Ariad Pharmaceuticals and Walmart Stores Inc. Released By InvestorsObserver
PR Newswire - Mon Jun 06, 9:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for CSIQ, BP, LL, ARIA and WMT.
WMT: 73.78 (+0.81), BP: 33.18 (-1.22), LL: 15.31 (+0.28), ARIA: 9.71 (+0.20), CSIQ: 14.77 (+0.57)
ARIAD's Investigational Medicine Brigatinib Demonstrates 54 Percent Confirmed Objective Response Rate and 12.9-Month Median Progression-Free Survival in ALTA Study
BusinessWire - Mon Jun 06, 6:35AM CDT
--~ Data from Pivotal Study in Refractory ALK Positive Non-Small Cell Lung Cancer Patients
ARIA: 9.71 (+0.20)
